According to the research report titled ‘Global Inflammatory Bowel Disease (IBD) Market - Analysis By Disease Indication (Crohn's Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)’, available with Market Study Report, global inflammatory bowel disease market was worth USD 210.5 billion in 2020 and is anticipated to grow momentously over 2021-2026.
 

Increasing incidence of crohn's disease and ulcerative colitis, developments in medical technology, assistance from government for treatment research, and prevalence of depression & anxiety are the factors impelling the growth of global inflammatory bowel disease market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3733205/
 

Additionally, unhealthy lifestyle of people, irregular food habits, increasing alcohol consumption, and cigarette smoking coupled with rising levels of pollution are causing higher risk of encountering fatal health conditions, thereby augmenting market scenario.
 

Moreover, rising investments for building a robust pipeline for inflammatory bowel disease medications, preference for probiotic and prebiotic foods, rise in geriatric population, improving healthcare infrastructure, and increased per capita expenditure on healthcare are adding to industry remuneration.
 

Based on disease indication, global inflammatory bowel disease (IBD) market is segmented into crohn’s disease, and ulcerative colitis. Speaking of drug class, the marketplace is divided into integrin antagonists, aminosalicylates, and TNF inhibitors among others. Moving on to distribution channel, the industry is classified into online pharmacies, retail pharmacies, and hospital pharmacies including others.
 

Regionally, North America inflammatory bowel disease market is poised to grow substantially over the forecast period, on account of large patient pool in the region. Moreover, presence of various biosciences and pharmaceutical companies in the region is positively swaying the market trends in North America.
 

Established firms in worldwide inflammatory bowel disease market sphere are Eli Lilly and Company, UCB S.A. (Union Chimique Belge), Novartis International AG, GlaxoSmithKline plc, Celgene Corporation, Roche Holding AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie, and Johnson & Johnson.